PCVX

Vaxcyte, Inc.

NasdaqGSUSDEQUITY DELAYED

62.85

▲ 1.51 (2.46%)

MARKET · —

Price

Open

61.34

Prev close

61.34

Day high

63.98

Day low

61.85

Volume

1.13M

Market cap

—

P/E (TTM)

—

52W range

29.87 – 65.00

Trailing performance

Price return · vs SPY

Returnvs SPY

+7.84% +9.2%

+12.54% +8.8%

+32.14% +29.0%

+7.02% -4.0%

YTD

+35.72% +23.4%

+100.32% +80.3%

+32.05% -42.1%

— —

Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.

Fundamentals

TTM · reported

Market cap—

Enterprise value—

Revenue (TTM)—

Gross profit—

EBITDA—

Net income—

EPS (TTM)—

Free cash flow—

Total cash—

Total debt—

Book value / share—

Shares outstanding—

Float—

Short % of float—

Dividend yield—

Beta (5Y)—

Valuation & profitability ratios

Account required

Trailing P/E—

Forward P/E—

PEG ratio—

Price / sales—

Price / book—

EV / revenue—

EV / EBITDA—

Gross margin—

Operating margin—

Profit margin—

Return on equity—

Return on assets—

Debt / equity—

Current ratio—

Free account required

Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.

Create free account Sign in

Analyst targets & ownership

Account required

Mean target—

High target—

Low target—

Implied upside—

Analyst count—

Consensus—

Strong buy / Buy— / —

Hold—

Sell / Strong sell— / —

Held by insiders—

Held by institutions—

Institutions holding—

Free account required

Price targets, consensus spread, insider and institutional ownership.

Create free account Sign in

Moving averages & technicals

Computed from 2Y daily closes

SMA 10

60.14

+4.51% from price

SMA 20

57.78

+8.38% from price

SMA 50

56.12

+11.57% from price

SMA 100

55.52

+13.20% from price

SMA 200

53.22

+17.66% from price

EMA 12

59.90

+4.93% from price

EMA 26

58.20

+7.99% from price

EMA 50

56.74

+10.76% from price

RSI (14)

62.6

Neutral

MACD (12,26,9)

1.70

Hist 0.48

ATR (14)

2.37

3.78% of price

Realised vol 30D

41.7%

Annualised

Bollinger upper

63.63

20, 2σ

Bollinger lower

51.92

20, 2σ

50 / 200 cross

Golden

56.12 vs 53.22

Trend bias

Above 200

+17.66%

Risk profile

Daily returns · 1Y window

Beta vs SPY

0.88

Less volatile than market

Correlation to SPY

0.25

Largely independent

Realised vol 30D

41.7%

Annualised

Market vol 1Y

12.9%

SPY, annualised

Max drawdown 1Y

-28.0%

Peak to trough

Max drawdown 5Y

-76.2%

Peak to trough

ATR 14

2.37

3.78% of price

Beta (reported)

—

5Y monthly, from filing

Options chain

Account required

ExpirySpot 62.85

Calls

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Puts

Strike	Last	Bid	Ask	Vol	OI	IV
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%
000.00	0.00	0.00	0.00	0	0	0.0%

Free account required

Every listed expiry, both sides of the book, with volume, open interest and implied volatility.

Create free account Sign in

Headlines

PCVX · links out to the publisher

If You Followed Seth Klarman Into Vaxcyte in May, He Was Already Long Gone 24/7 Wall St. · 6d ago ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer Business Wire · 11d ago Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update GlobeNewswire · 17d ago Vaxcyte to Participate in Upcoming Investor Conferences GlobeNewswire · 45d ago Vaxcyte Inc (PCVX) Is A Hidden Multibagger Stock To Buy Now Insider Monkey · 50d ago Vaxcyte Insider Sold Shares Worth $1,338,270, According to a Recent SEC Filing MT Newswires · 54d ago Vaxcyte (PCVX) Doses Its First Patient in a Trial for a Disease With No Existing Vaccine Insider Monkey · 61d ago Vaxcyte Insider Sold Shares Worth $1,284,205, According to a Recent SEC Filing MT Newswires · 61d ago

PRIVATE STRATEGY · BY QUALIFICATION

The same data. A different seat.

The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.